PRESS RELEASE
22 September 2022

Oppenhoff Advises Tesa SE On The Acquisition Of Tesa Labtec GmbH By Adhex Pharma

OP
Oppenhoff

Contributor

Oppenhoff is one of the leading independent law firms in Germany. We master the complex challenges of today and tomorrow - building on the experience of over 110 years of law firm history.

Our aspiration: through personal and comprehensive advice, we create economic added value and the best possible solutions for a changing world.

Oppenhoff advised tesa SE on the sale of tesa Labtec GmbH, a specialty pharmaceutical contract development and manufacturing organization for transdermal therapeutic systems and oral films, to Adhex Pharma.
Germany

Oppenhoff advised tesa SE on the sale of tesa Labtec GmbH, a specialty pharmaceutical contract development and manufacturing organization for transdermal therapeutic systems and oral films, to Adhex Pharma.

Adhex Pharma is a pharmaceutical company specialized in the field of development and manufacturing of transdermal patches, oral thin films and hard-to-make dosage forms. It is headquartered in Paris and part of Burgundy Ventures, an independent French industrial holding.

The Oppenhoff team led by Dr. Markus Rasner included Moritz Schmitz (M&A, Healthcare), Till Liebau, Marcel Markovic (both M&A), Dr. Marc Hilber, Patrick Schwarze (both IT&C), Anja Dombrowsky, Cornelia-Cristina Scupra (both Employment), Peter Klappich (Healthcare), Dr. Wolfgang Kotzur (Finance), Dr. Simon Spangler, Dr. Daniel Dohrn (both Antitrust) and Dr.Gunnar Knorr (Tax).

Oppenhoff regularly advises companies from the healthcare sector, most recently on the sale of the MVZ Nephrologicum Westfalen, Shop Apotheke on the acquisition of Smartpatient or the acquisition of the CNP Group by capiton.

Contributor

Oppenhoff is one of the leading independent law firms in Germany. We master the complex challenges of today and tomorrow - building on the experience of over 110 years of law firm history.

Our aspiration: through personal and comprehensive advice, we create economic added value and the best possible solutions for a changing world.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More